Previous 10 | Next 10 |
2023-08-16 09:31:41 ET Summary There is an ongoing phase 3 study, known as HOPE-3, deploying the use of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy; Interim analysis expected Q4 of 2023. A Type-B FDA meeting was held between the company and the FDA; Min...
2023-08-07 18:42:07 ET Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript August 07, 2023 04:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Presentatio...
2023-08-07 16:32:30 ET Capricor Therapeutics press release ( NASDAQ: CAPR ): Q2 GAAP EPS of -$0.29 beats by $0.06 . Revenue of $3.92M beats by $2.32M . The Company’s cash, cash equivalents and marketable securities totaled approximately $37.8 million as ...
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; On Track to Complete Enrollment and Report Interim Analysis in Fo...
2023-08-06 17:35:20 ET Major earnings expected after the bell on Monday include: Palantir Technologies ( PLTR ) Lucid Group ( LCID ) Skyworks Solutions ( SWKS ) Beyond Meat ( BYND ) Paramount Global ( PARA ) For further details see: Notabl...
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results fo...
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment o...
-John Hopkins School of Medicine Clinical Director Joins Capricor’s Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience- SAN DIEGO, July 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on th...
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function- -Results in Performance of the Upper Limb PUL v2.0 Continue to Show Long-Term Benefit in Skeletal Muscle Function (p=0.02)- -Safety and Efficacy Resu...
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company ...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre...